Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ochi A"'
Autor:
Akinori Yoda, Seishi Ogawa, Yosuke Minami, Keisuke Kataoka, Kotaro Shide, Kazuya Shimoda, Yasuyoshi Arikawa, Koji Izutsu, Ayako Kamiunten, Akio Mizutani, Daisuke Morishita, Hiroshi Miyake, Yotaro Ochi, Hirokazu Tozaki, Takuro Kameda
Publikováno v:
Blood. 136:3-4
Among various subtypes of malignant lymphomas, activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), mantle cell lymphoma (MCL), and adult T-cell leukemia/lymphoma (ATL) are clinically intractable as patients with these lymphomas carry a dismal
Autor:
Ying-Jung Huang, Seishi Ogawa, Yosaku Watatani, Yotaro Ochi, Kenichi Chiba, Ko Sasaki, Hiroko Tanaka, Noriko Hosoya, Akifumi Takaori-Kondo, Kinuko Mitani, Yuichi Shiraishi, Rabindranath Bera, Nobuhiro Hiramoto, Yasuhito Nannya, Takayuki Ishikawa, Masashi Sanada, Hideki Makishima, Kenichi Yoshida, June Takeda, Yusuke Shiozawa, Lee-Yung Shih, Satoru Miyano, Ming-Chung Kuo
Publikováno v:
Blood. 136:3-4
Background Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene. Despite the use of tyrosine kinase inhibitors (TKIs), a minority of chronic phase (CP) CML patients fail TKI therapies and progress to blast crisis (BC), showing
Autor:
Hideki Makishima, Keisuke Kataoka, Haruhiko Koseki, Yasuhito Nannya, Masahiro Nakagawa, Ayana Kon, Yotaro Ochi, Ryosaku Inagaki, Seishi Ogawa, Manabu Nakayama
Publikováno v:
Blood. 136:21-22
DDX41 is a newly identified leukemia predisposition gene encoding an RNA helicase, whose germline mutations are tightly associated with late-onset myeloid malignancies. Importantly, germline DDX41 mutations were also found in as many as ~7 % of spora
Autor:
Seishi Ogawa, Yoshihiko Satoh, Akinori Yoda, Yasuhito Nannya, Yotaro Ochi, Hiroshi Miyake, Hideki Makishima, Akio Mizutani, Daisuke Morishita
Publikováno v:
Blood. 134:404-404
Splicing factors (SFs) are among the most frequent mutational targets in myeloid neoplasms, particularly in myelodysplastic syndromes (MDS) and a subset of acute myeloid leukemia (AML), designated as 'chromatin/spliceosome-mutated AML, where major SF
Autor:
Ai Okada, Lee-Yung Shih, Akifumi Takaori-Kondo, Kenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yusuke Shiozawa, Ming-Chung Kuo, Yasuhito Nannya, Satoru Miyano, Yotaro Ochi, Ying-Jung Huang, Seishi Ogawa, Yuichi Shiraishi
Publikováno v:
Blood. 132:1725-1725
Background Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene. Despite the dramatic improvement of its prognosis in recent years by the development of tyrosine kinase inhibitors (TKIs), a minority of chronic phase (CP) CML pa
Autor:
Kiyotaka Kuzushima, Hiroshi Fujiwara, Koichiro Suemori, Toshiki Ochi, Yoshihiro Yakushijin, Taichi Azuma, Masaki Yasukawa, Takaaki Hato
Publikováno v:
Blood. 113:66-74
Aurora-A kinase (Aur-A) is a member of the serine/threonine kinase family that regulates the cell division process, and has recently been implicated in tumorigenesis. In this study, we identified an antigenic 9–amino-acid epitope (Aur-A207-215: YLI
Autor:
Hiroshi Fujiwara, Fumihiro Ochi, Toshiki Ochi, Hiroaki Asai, Yukihiro Miyazaki, Taichi Azuma, Sachiko Okamoto, Junichi Mineno, Miwako Narita, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Publikováno v:
Blood. 122:144-144
Purpose In the context of redirected T-cell based antitumor adoptive immunotherapy, the therapeutic roles played by co-infused CD4+ T cells genetically redirected to the predefined HLA class I-restricted epitope which had been originally recognized b
Autor:
Masaki Yasukawa, Toshiki Ochi, J. Joseph Melenhorst, Emma Gostick, Junichi Mineno, Jun An, Toshiaki Shirakata, Kozo Nagai, Eiichi Ishii, Hiroshi Fujiwara, Hiroshi Shiku, Kiyotaka Kuzushima, David Price
Publikováno v:
Blood. 119(2)
Aurora kinase A (AURKA) is overexpressed in leukemias. Previously, we demonstrated that AURKA-specific CD8+ T cells specifically and selectively lysed leukemia cells, indicating that AURKA is an excellent target for immunotherapy. In this study, we e
Autor:
Jun An, Kiyotaka Kuzushima, Toshiaki Shirakata, Junichi Mineno, Hiroshi Fujiwara, Sachiko Okamoto, Toshiki Ochi, Masaki Yasukawa, Kozo Nagai, Hiroshi Shiku
Publikováno v:
Blood. 118(6)
Adoptive T-cell therapy for malignancies using redirected T cells genetically engineered by tumor antigen-specific T-cell receptor (TCR) gene transfer is associated with mispairing between introduced and endogenous TCR chains with unknown specificity
Autor:
Sachiko Okamoto, Junichi Mineno, Masaki Yasukawa, Hiroshi Fujiwara, Hiroki Tanaka, Hiroaki Asai, Fumihiro Ochi, John Barrett, Kiyotaka Kuzushima, Hiroshi Shiku, Kazushi Tanimoto
Publikováno v:
Blood. 124:307-307
[Background and purpose] Mogamulizumab, a newly developed monoclonal antibody (mAb) targeting the receptor for C-C chemokine 4 (CCR4) has initially demonstrated a promising clinical outcome for the treatment of therapy-resistant Adult T cell leukemia